Impaired feedback inhibition of insulin secretion by hyperinsulinemia in patients with insulinoma. 1995

S Hiramatsu, and Y Sako, and K Mimura, and Y Ono, and K Iwashige, and S Taniguchi, and F Umeda, and H Nawata
Third Department of Internal Medicine, Faculty of Medicine, Kyushu University, Fukuoka, Japan.

By means of the euglycemic three step hyperinsulinemic clamp technique, suppression of endogenous C-peptide secretion by exogenous insulin infusion was evaluated in patients with insulinoma (n = 8) and healthy controls (n = 20). Euglycemic hyperinsulinemic clamp studies were performed with an artificial pancreas (STG-22 NIKKISO, Tokyo, Japan). Insulin (Actrapid human insulin) was infused at the rate of 1.12, 3, and 10 mU/kg/min. Plasma glucose levels were clamped at 80 mg/dl, and high insulin levels were maintained in all subjects (833 +/- 78 microU/ml at the rate of 10 mU/kg/min insulin infusion). During the clamp studies, plasma C-peptide levels in normal subjects declined from 2.0 +/- 0.2 to 0.9 +/- 0.2 ng/ml, indicating suppression of endogenous insulin secretion by exogenous insulin infusion. In patients with insulinoma, plasma C-peptide levels were 3.1 +/- 1.6 ng/ml in the basal state, and were not suppressed even during exogenous hyperinsulinemia. We concluded that the feedback inhibition of insulin secretion by exogenous insulin infusion is attenuated in patients with insulinoma, and that the hyperinsulinemic clamp technique may be a useful method for the diagnosis of insulinoma.

UI MeSH Term Description Entries
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D007340 Insulinoma A benign tumor of the PANCREATIC BETA CELLS. Insulinoma secretes excess INSULIN resulting in HYPOGLYCEMIA. Adenoma, beta-Cell,Insuloma,beta-Cell Tumor,Adenoma, beta Cell,Adenomas, beta-Cell,Insulinomas,Insulomas,Tumor, beta-Cell,Tumors, beta-Cell,beta Cell Tumor,beta-Cell Adenoma,beta-Cell Adenomas,beta-Cell Tumors
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010190 Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA). Cancer of Pancreas,Pancreatic Cancer,Cancer of the Pancreas,Neoplasms, Pancreatic,Pancreas Cancer,Pancreas Neoplasms,Pancreatic Acinar Carcinoma,Pancreatic Carcinoma,Acinar Carcinoma, Pancreatic,Acinar Carcinomas, Pancreatic,Cancer, Pancreas,Cancer, Pancreatic,Cancers, Pancreas,Cancers, Pancreatic,Carcinoma, Pancreatic,Carcinoma, Pancreatic Acinar,Carcinomas, Pancreatic,Carcinomas, Pancreatic Acinar,Neoplasm, Pancreas,Neoplasm, Pancreatic,Neoplasms, Pancreas,Pancreas Cancers,Pancreas Neoplasm,Pancreatic Acinar Carcinomas,Pancreatic Cancers,Pancreatic Carcinomas,Pancreatic Neoplasm
D002096 C-Peptide The middle segment of proinsulin that is between the N-terminal B-chain and the C-terminal A-chain. It is a pancreatic peptide of about 31 residues, depending on the species. Upon proteolytic cleavage of proinsulin, equimolar INSULIN and C-peptide are released. C-peptide immunoassay has been used to assess pancreatic beta cell function in diabetic patients with circulating insulin antibodies or exogenous insulin. Half-life of C-peptide is 30 min, almost 8 times that of insulin. Proinsulin C-Peptide,C-Peptide, Proinsulin,Connecting Peptide,C Peptide,C Peptide, Proinsulin,Proinsulin C Peptide
D005246 Feedback A mechanism of communication within a system in that the input signal generates an output response which returns to influence the continued activity or productivity of that system. Feedbacks
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

S Hiramatsu, and Y Sako, and K Mimura, and Y Ono, and K Iwashige, and S Taniguchi, and F Umeda, and H Nawata
May 1982, The New England journal of medicine,
S Hiramatsu, and Y Sako, and K Mimura, and Y Ono, and K Iwashige, and S Taniguchi, and F Umeda, and H Nawata
December 1986, The Journal of clinical endocrinology and metabolism,
S Hiramatsu, and Y Sako, and K Mimura, and Y Ono, and K Iwashige, and S Taniguchi, and F Umeda, and H Nawata
January 2000, Clinical endocrinology,
S Hiramatsu, and Y Sako, and K Mimura, and Y Ono, and K Iwashige, and S Taniguchi, and F Umeda, and H Nawata
January 1993, Acta diabetologica,
S Hiramatsu, and Y Sako, and K Mimura, and Y Ono, and K Iwashige, and S Taniguchi, and F Umeda, and H Nawata
October 1992, Journal of the American Society of Nephrology : JASN,
S Hiramatsu, and Y Sako, and K Mimura, and Y Ono, and K Iwashige, and S Taniguchi, and F Umeda, and H Nawata
October 1981, Clinical endocrinology,
S Hiramatsu, and Y Sako, and K Mimura, and Y Ono, and K Iwashige, and S Taniguchi, and F Umeda, and H Nawata
January 1976, The Netherlands journal of medicine,
S Hiramatsu, and Y Sako, and K Mimura, and Y Ono, and K Iwashige, and S Taniguchi, and F Umeda, and H Nawata
September 1981, Acta endocrinologica,
S Hiramatsu, and Y Sako, and K Mimura, and Y Ono, and K Iwashige, and S Taniguchi, and F Umeda, and H Nawata
July 1990, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.),
S Hiramatsu, and Y Sako, and K Mimura, and Y Ono, and K Iwashige, and S Taniguchi, and F Umeda, and H Nawata
January 2024, The Journal of clinical endocrinology and metabolism,
Copied contents to your clipboard!